The transgenic technology is today an integrated part of biomedical research, and the need to generate transgenic animals with specific genetic alterations is steadily increasing. We are therefore happy to inform you that the capacity to produce transgenic mice has been significantly improved at KI, and we would like to take this opportunity to welcome you as potential customers in this core facility.

In 1991 two independent transgenic core facilities were established at the Karolinska Institute, one at the KI South-Campus at Huddinge University Hospital / Ovum, Unit for Embryology and Genetics (formerly MEG) and one at the KI North-Campus at the Department of Cell and Molecular Biology (CMB) named Mouse Camp. After an international evaluation of both core facilities, the scientific board of the KI decided to merge the two existing facilities, to increase the capacity and to take better advantage of the existing scientific expertise.

KCTT is a non-commercial, non-profit academic core facility and is still located at both sites, to serve the researcher at both places and to have a security backup in case of infections in one of the production units. The aim of KCTT is to produce transgenic mice by the pronuclear injection and ES cell techniques for research groups at the Karolinska Institute, the Karolinska Hospital, Huddinge Hospital and research groups at other academic institutions. Groups from Industry should contact Karolinska Research Services AB for further information.

KCTT is one of the largest transgenic core facilities in Scandinavia with a yearly number of 60 - 70 constructs for pronucleus injection, around 30 - 40 electroporations of knockout constructs and 40 - 50 injected ko constructs of targeted ES cells.

28-Mar-2011